James Silverman
@Opaleye Management Inc.
Latest period2024 - Q3ReportedManaged Assets$599.558MTotal holdings44
Assets growth rate37%Assets growth rate (2-Q avg)16.19%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Opaleye Management Inc.'s 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 44 positions.
Assets under management
The assets under management (AUM) of Opaleye Management Inc. over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 599.558M in assets, with a quarterly growth rate of 37% and a 2-quarter average growth rate of 16.19%. The portfolio is managed by James Silverman, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
EWTXEdgewise Therapeutics Inc
| 2.33% | $13.946M 522,500 shares@ $26.69 avg price | Decreased -9.91% |
CRGXCargo Therapeutics Inc
| 1.98% | $11.835M 541,437 shares@ $21.86 avg price | Decreased -2.56% |
APLTApplied Therapeutics Inc'
| 1.88% | $11.22M 1.32M shares@ $8.5 avg price | Decreased -21.42% |
PCVXVaxcyte Inc
| 1.63% | $9.713M 85,000 shares@ $114.27 avg price | |
NRIXNurix Therapeutics Inc
| 1.58% | $9.437M 420,000 shares@ $22.47 avg price | Increased 0.26% |
SLRNAcelyrin Inc
| 1.56% | $9.336M 1.894M shares@ $4.94 avg price | Increased 19.86% |
TRVITrevi Therapeutics Inc
| 1.44% | $8.577M 2.568M shares@ $3.35 avg price | Decreased -2.91% |
BDSXBiodesix Inc
| 1.17% | $6.971M 3.815M shares@ $1.83 avg price | Decreased -5.09% |
DNAGinkgo Bioworks Holdings
| 1.12% | $6.685M 820,202 shares@ $8.15 avg price | New Position |
JSPRJasper Therapeutics Inc
| 1.11% | $6.649M 353,500 shares@ $18.81 avg price | Decreased -9.82% |